1-5 of 5
Marjorie G. Zauderer
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Diffuse Pleural Mesotheliomas with Genomic Near-Haploidization: A Newly Recognized Subset with Distinct Clinical, Histologic, and Molecular Features

Soo-Ryum Yang, Gowtham Jayakumaran, Jamal Benhamida, Christopher A. Febres-Aldana, Rachel Fanaroff, Jason Chang, Erika Gedvilaite, Liliana B. Villafania, Jennifer L. Sauter, Michael Offin, Marjorie G. Zauderer, Marc Ladanyi
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (13): 2780–2789.
https://doi.org/10.1158/1078-0432.CCR-24-0085
Published: 01 July 2024
View article titled, Diffuse Pleural Mesotheliomas with Genomic Near-Haploidization: A Newly Recognized Subset with Distinct Clinical, Histologic, and Molecular Features
Open the PDF for Diffuse Pleural Mesotheliomas with Genomic Near-Haploidization: A Newly Recognized Subset with Distinct Clinical, Histologic, and Molecular Features in another window
Includes: Supplementary data
Journal Articles

Nivo-lution in Mesothelioma

Aaron S. Mansfield, Marjorie G. Zauderer
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (18): 5438–5440.
https://doi.org/10.1158/1078-0432.CCR-19-1836
Published: 13 September 2019
View article titled, Nivo-lution in Mesothelioma
Open the PDF for Nivo-lution in Mesothelioma in another window
Journal Articles

A Randomized Phase II Trial of Adjuvant Galinpepimut-S, WT-1 Analogue Peptide Vaccine, After Multimodality Therapy for Patients with Malignant Pleural Mesothelioma

Marjorie G. Zauderer, Anne S. Tsao, Tao Dao, Katherine Panageas, W. Victoria Lai, Andreas Rimner, Valerie W. Rusch, Prasad S. Adusumilli, Michelle S. Ginsberg, Daniel Gomez, David Rice, Reza Mehran, David A. Scheinberg, Lee M. Krug
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (24): 7483–7489.
https://doi.org/10.1158/1078-0432.CCR-17-2169
Published: 14 December 2017
View article titled, A Randomized Phase II Trial of Adjuvant Galinpepimut-S, WT-1 Analogue Peptide Vaccine, After Multimodality Therapy for Patients with Malignant Pleural Mesothelioma
Open the PDF for A Randomized Phase II Trial of Adjuvant Galinpepimut-S, WT-1 Analogue Peptide Vaccine, After Multimodality Therapy for Patients with Malignant Pleural Mesothelioma in another window
Includes: Supplementary data
Journal Articles

Phase I Study of Apitolisib (GDC-0980), Dual Phosphatidylinositol-3-Kinase and Mammalian Target of Rapamycin Kinase Inhibitor, in Patients with Advanced Solid Tumors

Saoirse O. Dolly, Andrew J. Wagner, Johanna C. Bendell, Hedy L. Kindler, Lee M. Krug, Tanguy Y. Seiwert, Marjorie G. Zauderer, Martijn P. Lolkema, Doris Apt, Ru-Fang Yeh, Jill O. Fredrickson, Jill M. Spoerke, Hartmut Koeppen, Joseph A. Ware, Jennifer O. Lauchle, Howard A. Burris, 3rd, Johann S. de Bono
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (12): 2874–2884.
https://doi.org/10.1158/1078-0432.CCR-15-2225
Published: 14 June 2016
View article titled, Phase I Study of Apitolisib (GDC-0980), Dual Phosphatidylinositol-3-Kinase and Mammalian Target of Rapamycin Kinase Inhibitor, in Patients with Advanced Solid Tumors
Open the PDF for Phase I Study of Apitolisib (GDC-0980), Dual Phosphatidylinositol-3-Kinase and Mammalian Target of Rapamycin Kinase Inhibitor, in Patients with Advanced Solid Tumors in another window
Includes: Supplementary data
Journal Articles

New Strategies in Pleural Mesothelioma: BAP1 and NF2 as Novel Targets for Therapeutic Development and Risk Assessment

Marc Ladanyi, Marjorie G. Zauderer, Lee M. Krug, Tatsuo Ito, Robert McMillan, Matthew Bott, Filippo Giancotti
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (17): 4485–4490.
https://doi.org/10.1158/1078-0432.CCR-11-2375
Published: 30 August 2012
View article titled, New Strategies in Pleural Mesothelioma: BAP1 and NF2 as Novel Targets for Therapeutic Development and Risk Assessment
Open the PDF for New Strategies in Pleural Mesothelioma: BAP1 and NF2 as Novel Targets for Therapeutic Development and Risk Assessment in another window